These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
319 related articles for article (PubMed ID: 11793474)
1. Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein. Martin AC; Facchiano AM; Cuff AL; Hernandez-Boussard T; Olivier M; Hainaut P; Thornton JM Hum Mutat; 2002 Feb; 19(2):149-64. PubMed ID: 11793474 [TBL] [Abstract][Full Text] [Related]
2. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations. Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393 [TBL] [Abstract][Full Text] [Related]
3. The impact of p53 protein core domain structural alteration on ovarian cancer survival. Rose SL; Robertson AD; Goodheart MJ; Smith BJ; DeYoung BR; Buller RE Clin Cancer Res; 2003 Sep; 9(11):4139-44. PubMed ID: 14519637 [TBL] [Abstract][Full Text] [Related]
4. Have p53 gene mutations and protein expression a different biological significance in colorectal cancer? Bazan V; Migliavacca M; Tubiolo C; Macaluso M; Zanna I; Corsale S; Amato A; Calò V; Dardanoni G; Morello V; La Farina M; Albanese I; Tomasino RM; Gebbia N; Russo A J Cell Physiol; 2002 May; 191(2):237-46. PubMed ID: 12064467 [TBL] [Abstract][Full Text] [Related]
5. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Kato S; Han SY; Liu W; Otsuka K; Shibata H; Kanamaru R; Ishioka C Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8424-9. PubMed ID: 12826609 [TBL] [Abstract][Full Text] [Related]
6. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters. Baumbusch LO; Myhre S; Langerød A; Bergamaschi A; Geisler SB; Lønning PE; Deppert W; Dornreiter I; Børresen-Dale AL Mol Cancer; 2006 Oct; 5():47. PubMed ID: 17054774 [TBL] [Abstract][Full Text] [Related]
7. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573 [TBL] [Abstract][Full Text] [Related]
8. Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods. Mathe E; Olivier M; Kato S; Ishioka C; Hainaut P; Tavtigian SV Nucleic Acids Res; 2006; 34(5):1317-25. PubMed ID: 16522644 [TBL] [Abstract][Full Text] [Related]
9. Loss of TP53-DNA interaction induced by p.C135R in lung cancer. Aranda M; Gonzalez-Nilo F; Riadi G; Díaz V; Perez J; Martel G; Hainaut P; Mimbacas A Oncol Rep; 2007 Nov; 18(5):1213-7. PubMed ID: 17914575 [TBL] [Abstract][Full Text] [Related]
10. [TP53 mutations and molecular epidemiology]. Otsuka K; Ishioka C Gan To Kagaku Ryoho; 2007 May; 34(5):683-9. PubMed ID: 17496437 [TBL] [Abstract][Full Text] [Related]
11. Detailed computational study of p53 and p16: using evolutionary sequence analysis and disease-associated mutations to predict the functional consequences of allelic variants. Greenblatt MS; Beaudet JG; Gump JR; Godin KS; Trombley L; Koh J; Bond JP Oncogene; 2003 Feb; 22(8):1150-63. PubMed ID: 12606942 [TBL] [Abstract][Full Text] [Related]
12. [P53 at the atomic scale: the multiple faces of a crystal]. Hainaut P Bull Cancer; 1997 Jul; 84(7):747-51. PubMed ID: 9339202 [TBL] [Abstract][Full Text] [Related]
13. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Bullock AN; Henckel J; Fersht AR Oncogene; 2000 Mar; 19(10):1245-56. PubMed ID: 10713666 [TBL] [Abstract][Full Text] [Related]
14. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Petitjean A; Mathe E; Kato S; Ishioka C; Tavtigian SV; Hainaut P; Olivier M Hum Mutat; 2007 Jun; 28(6):622-9. PubMed ID: 17311302 [TBL] [Abstract][Full Text] [Related]
15. Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features. Walker DR; Bond JP; Tarone RE; Harris CC; Makalowski W; Boguski MS; Greenblatt MS Oncogene; 1999 Jan; 18(1):211-8. PubMed ID: 9926936 [TBL] [Abstract][Full Text] [Related]
16. Structural assessment of single amino acid mutations: application to TP53 function. Yip YL; Zoete V; Scheib H; Michielin O Hum Mutat; 2006 Sep; 27(9):926-37. PubMed ID: 16917930 [TBL] [Abstract][Full Text] [Related]
17. Structure, function, and aggregation of the zinc-free form of the p53 DNA binding domain. Butler JS; Loh SN Biochemistry; 2003 Mar; 42(8):2396-403. PubMed ID: 12600206 [TBL] [Abstract][Full Text] [Related]
18. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Greenblatt MS; Bennett WP; Hollstein M; Harris CC Cancer Res; 1994 Sep; 54(18):4855-78. PubMed ID: 8069852 [No Abstract] [Full Text] [Related]
19. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332 [TBL] [Abstract][Full Text] [Related]
20. The effect of mutations on peptide models of the DNA binding helix of p53: evidence for a correlation between structure and tumorigenesis. Trulson JA; Millhauser GL Biopolymers; 1999 Mar; 49(3):215-24. PubMed ID: 9990839 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]